MVX-220

MVX-220 is an investigational gene therapy developed for the treatment of Angelman syndrome. It utilizes an adeno-associated virus (AAV) vector, specifically the hu68AAV serotype, to deliver a functional copy of the human UBE3A gene directly to neurons in the brain. The loss of function or mutation in the maternal UBE3A gene is the underlying cause of Angelman syndrome, leading to severe neurodevelopmental symptoms. By restoring neuronal expression of UBE3A through targeted AAV-mediated delivery, MVX-220 aims to address the root genetic defect and potentially provide a single-treatment cure for affected individuals. Preclinical studies have shown that this approach can restore UBE3A protein levels and alleviate disease symptoms in mouse models. The therapy is being advanced into first-in-human Phase 1/2 clinical trials (ASCEND-AS), which will evaluate its safety, tolerability, and preliminary efficacy in both adult and pediatric patients with various genotypes of Angelman syndrome[2][3][5][7][8].